SCHEMBL25344930

SCHEMBL25344930

Cn1c(=O)cc(O)c2cnn(-c3ccc(F)cc3F)c21

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.57
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.44
CYP17A1 P05093 2/20 0.42
CYP1A2 P05177 1/20 0.42
LCK P06239 1/20 0.41
KIT P10721 1/20 0.41
KDR P35968 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25343704 0.85 MAPK14 (0.56) MAPK14CYP2D6CYP2C9CYP2C19L3MBTL1
SCHEMBL25341635 0.82 MAPK14 (0.48) MAPK14CYP2D6CYP2C9CYP2C19L3MBTL1
SCHEMBL25343661 0.81 MAPK14 (0.44) MAPK14CYP2D6CYP2C9CYP2C19CYP17A1
SCHEMBL4134853 0.80 MAPK14 (0.52) MAPK14CYP17A1CYP1A2
SCHEMBL4123815 0.75 MAPK14 (0.72) MAPK14CYP2D6CYP2C9CYP2C19
SCHEMBL10624240 0.74 L3MBTL1 (0.54) MAPK14CYP2D6CYP2C9CYP2C19L3MBTL1
SCHEMBL31260837 0.71 MAPK14 (0.39) MAPK14CYP2D6CYP2C9CYP2C19
SCHEMBL31260933 0.70 PIK3CB (0.34) MAPK14CYP2D6CYP2C9CYP2C19
SCHEMBL1883322 0.69 MAPK14 (0.44) MAPK14CYP2D6CYP2C9CYP2C19L3MBTL1
SCHEMBL25343725 0.69 CYP17A1 (0.46) MAPK14L3MBTL1CYP17A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4472739-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2024-12-11 EP disclosed
WO-2023148129-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2023-08-10 WO disclosed